OraSure Technologies on Wednesday announced that the Food and Drug Administration's Blood Products Advisory Committee will consider making its OraQuick Rapid HIV-1/2 test available over the counter on May 15.
Patients with HIV who immediately started antiretroviral therapy significantly reduced the risk of spreading the virus to an uninfected partner, compared with those who delayed therapy, according to results of a multinational study. The study also found that antiretroviral therapy reduced the risk of transmission by 96%.
